The AI partner behind an AI-native biotech

Prosemble.bio is already an AI-native company - the question was never whether to use generative AI, but how far to take it. Moterra started with a Rapid AI Assessment scoped around four strategic biotech initiatives, and stayed on as Prosemble’s AI partner: an extended team adding generative AI capability to their propositions as new opportunities arise.

Prosemble.bio is a UK biotechnology company building a vertically integrated therapeutics platform powered by AI and nanotechnology - engineering protein-based nanoparticle systems to deliver drugs more precisely and reduce side effects. For a company already built on AI, the strategic question was where generative AI would create defensible leverage next, and who could be trusted as a long-term AI partner in a highly regulated, IP-sensitive environment.

An evidence-based view, and a partner who could stay engaged as the science evolves.

A Rapid AI Assessment scoped around four strategic initiatives identified with Prosemble’s team: retrieval-augmented reasoning over toxicological literature, a molecular Q&A agent for research teams, an AI-enhanced molecule visualiser, and a cost and risk model for portfolio decisions.

Beyond the assessment, Moterra now operates as Prosemble’s ongoing AI partner - an extended team adding generative AI capability into their biotech propositions as new initiatives and partnerships emerge, with Moterra Business AI Suite as the shared platform for rapid MVP work and validation.

Prosemble’s leadership got both: a defensible AI plan grounded in evidence, and an ongoing partner able to bring generative AI into every new biotech initiative - the kind of long-term foundation that regulators, investors and partners in pharmaceutical research expect.

What problem did Prosemble.bio need to solve?

Prosemble.bio is a UK biotechnology company building a vertically integrated therapeutics platform powered by AI and nanotechnology - engineering protein-based nanoparticle systems to deliver drugs more precisely and reduce side effects. For a company already built on AI, the strategic question was where generative AI would create defensible leverage next, and who could be trusted as a long-term AI partner in a highly regulated, IP-sensitive environment.

What did Moterra deploy for Prosemble.bio?

A Rapid AI Assessment scoped around four strategic initiatives identified with Prosemble’s team: retrieval-augmented reasoning over toxicological literature, a molecular Q&A agent for research teams, an AI-enhanced molecule visualiser, and a cost and risk model for portfolio decisions.

What results did Prosemble.bio see?

Prosemble’s leadership got both: a defensible AI plan grounded in evidence, and an ongoing partner able to bring generative AI into every new biotech initiative - the kind of long-term foundation that regulators, investors and partners in pharmaceutical research expect.

Where does the deployment run?

Inside the client’s own cloud tenant, in the region they choose. The deployment is Private Claude Cowork by Moterra, with admin, MDM and governance handled by Moterra AI Bridge. Moterra builds in AWS and Azure, operates as a data processor under a DPA covering UK and EU GDPR, and the stack is ISO 27001 and ISO 42001 certified across the AWS and Anthropic layers.

How long does a deployment like this take?

Standard deployment is typically live within one to two weeks, covering environment and region setup, the identity path from your SSO, managed configuration through your MDM, and the connector allowlist.

Bring the hardest questions to the first call.

Thirty minutes, a live demo, and a quote for your environment.

Moterra is a private AI deployment company and a Select Services Partner in the Claude Partner Network. We help businesses deploy Claude inside their own AWS or Azure environment, connect it to the tools they already use, and keep it secure and governed, so everyday processes get faster.

Solutions

Company